Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences

2014-09-05

2014

Κοπιτοπούλου Αλεξάνδρα

Καθηγητής Κωνσταντίνος Συρίγος, Λέκτορας Γρηγόριος Στρατάκος, Διδάκτωρ Ιωάννης Ντάνος

Επιδημιολογικά χαρακτηριστικά ασθενών με EGFR θετικά αδενοκαρκινώματα πνεύμονος και η κλινική τους σημασία

Greek

Abstract
Rationale: This study is a retrospective analysis of Response, Progression
Free Survival and Overall Survival in patients with EGFR mutated lung
adenocarcinomas treated with EGFR Tyrosine Kinase Inhibitors (TKIs), in
relation to specific epidemiological traits.
Patients/Methods: Inclusion criteria were a histological diagnosis of lung
adenocarcinoma, the presence of an EGFR mutation, disease stage III – IV and
treatment with EGFR TKIs. The traits studied were age, sex, smoking status, the
presence of brain and bone metastases, the presence of markers TTF-1 and Ki67,
the specific exon of EGFR mutation and the development of diarrhea and rash
with treatment.
Results: The study included 23 patients with EGFR mutated lung adenocarcinomas.
Women demonstrated statistically significant better Overall Survival, as did
patients who developed rash and patients who had Complete or Partial Response
with treatment. There was no statistically significant difference in
Progression Free Survival in any group of patients. Response could not be
assessed statistically due to small sample size. 22 of the biopsy specimens
were evaluated for the presence of TTF-1 and 95.5% were found positive for the
marker.
Discussion: In current literature, women with Non Small Cell Lung Cancer of any
type are demonstrated to have an increased survival compared to men. The
survival advantage for women with EGFR mutated lung adenocarcinomas
demonstrated in this study is, to our knowledge, a new finding. The improved
survival of patients, who developed rash with EGFR TKIs, is a well established
fact and is in accordance with international studies. As expected, patients
with Complete or Partial Response had statistically significant better Overall
Survival compared to patients who had Stable or Progressive Disease. The
positivity of the marker TTF-1 in 95.5% of these EGFR mutated lung
adenocarcinomas is in accordance with current literature, suggesting that the
presence of EGFR and TTF-1 is strongly correlated.

Lung Adenocarcinoma, Lung, Molecular marker, Women, Men

No

0

Yes

71

53

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/1311162